2017

• patent2017/12/26

  India Patent Office Granted AskAt a Substance Patent of 5-HT4 Receptor Agonist (AAT-009)

  AskAt Inc. announced today that AskAt received a notice of allowance dated December 19, 2017 from Office of the Controller General of Patent, Designs & Trade Marks in connection with the Application No. 762/DELNP/2006, a substance patent for its 5-HT4 Receptor Agonist (AAT-009)

• business2017/12/18

  Investigational new drug application for EP4 antagonist AAT-007 was approved by the National Food and Drug Administration of the People's Republic of China

  RMX Biopharma Co., Ltd (Headquarters in Hangzhou, China, CEO: RuiPing Dong, RMX), which licensed AskAt’s EP4 antagonist AAT-007 (generic name: grapiprant) for pain indications in People’s Republic of China (China), submitted an investigational new drug (IND) application to the State Food and Drug Administration and Supervision Authority of China (CFDA) and the IND has been accepted.

• business2017/12/14

  AskAt Inc. Announces Global Immuno-Oncology Licensing Agreement with Arrys Therapeutics Inc.

  December 14, 2017, Nagoya, Japan – AskAt Inc. (AskAt), a bio-pharmaceutical venture company headquartered in Nagoya, Japan (Akihiro Furuta, President), today announced a worldwide licensing agreement in immuno-oncology with Arrys Therapeutics, Inc. (Arrys) for two, structurally different Prostaglandin E2 receptor 4 (EP4) antagonists [AAT-007 and AAT-008].

• company2017/09/06

  News Article featuring AskAt in YAKUJINIPPO

  News Article featuring AskAt in YAKUJINIPPO on September 6, 2017, entitled “[AskAt] From Development in China to Worldwide Market Introduction, Expanding a Pain Therapeutic to Cancer”
  
  

• patent2017/09/05

  Japan Patent Office Granted AskAt a Salt & Crystal Forms Patent of COX-2 Inhibitor

  AskAt Inc. announced today that AskAt received a notice of allowance dated September 5, 2017 from Japan Patent Office in connection with the Application No. 2015-527377, a salt and crystal forms patent for its COX II Inhibitor (AAT-076).

• patent2017/09/01

  Autoimmune disease Use Patent for EP4 antagonist Approved in Korea

  AskAt received a notice of allowance dated September 1, 2017 from Korea Intellectual Property Rights Information Service (KIPRS) in connection with the Application No. 10-2012-7024115, a use patent of EP4 antagonist.

• patent2017/07/12

  Dementia Use Patent for 5-HT4 Receptor Agonist (AAT-009) Approved in EU

  AskAt received a notice of allowance dated July 12, 2017 from EU patent office in connection with the Application No. 11742054.7, a use patent of 5-HT4 receptor agonist for dementia.

• patent2017/06/30

  India Patent Office Granted AskAt a Substance Patent of EP4 antagonist(AAT-007)

  AskAt Inc. announced today that AskAt received a notice of allowance dated June 30, 2017 from Office of the Controller General of Patent, Designs & Trade Marks in connection with the Application No. 817/DELNP/2006, a substance patent for its EP4 antagonist(AAT-007)

• patent2017/06/17

  China Patent Office Granted AskAt a Salt & Crystal Forms Patent of COX-2 Inhibitor (AAT-076)

  AskAt Inc. announced today that AskAt received a notice of allowance dated June 17, 2017 from State Intellectual Property Office of the P.R.C. (SIPO) in connection with the Application No. 201480003563.4, a salt and crystal forms patent for its COX II Inhibitor (AAT-076).

• company2017/05/10

  AskAt completed an 50,000,000 yen financing from Ningbo Tai Kang Medical Technology Co., Ltd

  AskAt Inc. announced today that the company issued an allocation of new shares to Ningbo Tai Kang Medical Technology Co., Ltd in China.

• patent2017/04/25

  Autoimmune disease Use Patent for EP4 antagonist Approved in Japan

  AskAt received a notice of allowance dated April 25, 2017 from the Japanese Patent Office in connection with the Application No. 2012-538520, a use patent of EP4 antagonist.

• patent2017/03/30

  Treatment of Cancer Use Patent for EP4 antagonist Approved in US

  AskAt received a notice of allowance dated March 30. 2017 from the United States Patent and Trademark Office (USPTO) in connection with the Application No. 14/547,247, a use patent of EP4 receptor antagonist for the treatment of Cancer.
  

• patent2017/02/27

  Dementia Use Patent for 5-HT4 Receptor Agonist (AAT-009) Approved in Korea

  AskAt received a notice of allowance dated February 27, 2017 from Korea Intellectual Property Rights Information Service (KIPRS) in connection with the Application No. 10-2012-7023644, a use patent of 5-HT4 receptor agonist for dementia.
  

• business2017/01/24

  Galliprant® Now Available for Canine Osteoarthritis

  Elanco Animal Health and Aratana Therapeutics Inc. have announced that Galliprant® is now available for the management of pain and inflammation associated with canine osteoarthritis (OA) in the USA.